[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-356438-105":59,"doc-detail-356438-en":135},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":128,"head_meta":130,"extra_data":132,"updated_unix":134},105,"en","secondary-primary-malignancies-in-indolent-non-hodgkin-lymphoma-patients-receiving-frontline-bendamustine-rituximab","Secondary primary malignancies in indolent non-Hodgkin lymphoma patients receiving frontline bendamustine-rituximab","","Bendamustine-rituximab (BR) is a common frontline therapy for indolent B-cell non-Hodgkin lymphomas, yet its relationship with secondary primary malignancies (SPM) is not well established. A population-based Ontario study compared adults receiving BR (2013–2022) with a historical cohort treated with cyclophosphamide-based regimens (2006–2012). Five-year SPM incidence was assessed using competing-risk models, with landmark analysis at 6 months. BR showed higher univariate SPM risk and SPM reduced survival, but multivariable analyses found no significant difference, while more BR cycles indicated borderline increased risk.",{"@graph":69,"@context":127},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/secondary-primary-malignancies-in-indolent-non-hodgkin-lymphoma-patients-receiving-frontline-bendamustine-rituximab/356438/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/secondary-primary-malignancies-in-indolent-non-hodgkin-lymphoma-patients-receiving-frontline-bendamustine-rituximab/356438.png","ImageObject",300,407,{"name":92,"@type":93},"Riley","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119,123],{"name":110,"@type":111,"acceptedAnswer":112},"What therapy and patient population were studied?","Question",{"text":113,"@type":114},"The study evaluated frontline bendamustine-rituximab (BR) in adults (≥18 years) with untreated indolent B-cell non-Hodgkin lymphoma treated between 2013 and 2022, compared with a historical cohort treated with cyclophosphamide-based regimens between 2006 and 2012.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How was secondary primary malignancy (SPM) incidence measured?",{"text":118,"@type":114},"Five-year SPM incidence was analyzed using cumulative incidence function with competing-risk models, and a landmark analysis was performed at 6 months after the index date.",{"name":120,"@type":111,"acceptedAnswer":121},"Did BR increase SPM risk compared with the older cyclophosphamide-based regimens?",{"text":122,"@type":114},"The 5-year cumulative incidence of SPM was higher for BR versus the historical regimens in univariate comparisons, but multivariable analysis showed no significant difference in SPM risk.",{"name":124,"@type":111,"acceptedAnswer":125},"What was the effect of developing SPM on survival?",{"text":126,"@type":114},"Development of SPM shortened survival, with a hazard ratio reported as HR 3.67 (95% CI, 3.15–4.29, p \u003C .001).","https://schema.org",{"og:url":83,"og:type":129,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":131,"canonical":83},"index,follow",{"doc_id":133,"site_id":62},356438,1790536112,{"code":4,"msg":5,"data":136},{"doc_id":133,"user_id":137,"nickname":92,"user_avatar":138,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":139,"file_id":140,"file_url":141,"file_type":142,"file_size":143,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":19,"preview_urls":150},1374391975076,"https://ap-avatar.wpscdn.com/avatar/14000253ca4ec9f6853?x-image-process=image/resize,m_fixed,w_180,h_180&k=1783305029341752051","DOI: 10. 1002/cncr.70327  \nORIGINAL ARTICLE  \nSecondary primary malignancies in indolent non-Hodgkin lymphoma patients receiving frontline bendamustinerituximab  \nGwynivere A. Davies MD, MPH1,2,3  | Anca Prica MD4,5 | Zharmaine Ante PhD6 | Ning Liu PhD6 | Gregory R. Pond PhD1,3 | Amaris K. Balitsky MD, MSC1,2,3  | Adam Suleman MD5 | Lee Mozessohn MD, MPH4,6,7   \n1Department of Oncology, McMaster University, Hamilton, Ontario, Canada 2Hamilton Health Sciences, Juravinski Cancer Center, Hamilton, Ontario, Canada 3Escarpment Cancer Research Institute, Hamilton, Ontario, Canada  \n4Department of Medicine, University of Toronto, Toronto, Ontario, Canada 5Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada  \n6Cancer Research Program, ICES, Toronto, Ontario, Canada  \n7Division of Medical Oncology and Hematology, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada  \nCorrespondence  \nGwynivere A. Davies, FRCPC Juravinski Cancer Centre, McMaster University, 699 Concession St, Hamilton, ON L8V 5C2, Canada.  \nEmail: [daviesg@hhsc.ca](daviesg@hhsc.ca)  \nFunding information  \nJuravinski Hospital & Cancer Centre  \nFoundation, Grant/Award Number: RD-231  \nAbstract  \nBackground: Bendamustine-rituximab (BR) is common frontline therapy for indolent B-cell non-Hodgkin lymphomas (iBCL), but its association with secondary primary malignancies (SPM) is unclear.  \nMethods: The authors conducted a population-based study using linked Ontario health care databases. Patients ≥18 years old with untreated iBCL receiving BR (2013–2022) were compared to a historical cohort receiving cyclophosphamidebased regimens (rituximab, cyclophosphamide, vincristine, prednisone/rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone [R-CVP/CHOP], 2006–2012). Five-year SPM incidence was assessed using cumulative incidence function and competing risk models. Landmark analysis was conducted at 6 months after index date.  \nResults: A total of 6878 patients (BR, 4611; R-CVP/CHOP, 2267) were identified; BR recipients were older (65.6 vs. 62.8 years, p \u003C .001). The 5-year cumulative incidence of SPM was higher with BR versus R-CVP/CHOP (8. 9% vs. 7. 2%, p = .019) as was the SPM rate at 6.4 versus 4.9 per 100,000 person-days (p = .006), with higher rates of respiratory tract, male genitourinary, and skin cancers. Myelodysplastic syndrome/acute myeloid leukemia cases were similar accounting for group size (n = 23 vs. 11, p = . 20). Multivariable analysis showed no significant difference in SPM risk (hazard ratio [HR], 1. 13; 95% CI, 0.93–1. 36, p = . 22); full versus abbreviated BR was associated with borderline higher SPM risk (cumulative incidence function, 10. 7% vs. 7. 2%; HR, 1. 51, p = .06). No difference was seen by cycles for R-CVP/CHOP. Development of SPM shortened survival (HR, 3. 67; 95% CI, 3.15–4. 29, p \u003C .001).  \nConclusions: Although BR patients demonstrated a higher SPM risk at 5 years in univariate models, this finding was not present on multivariable analysis. An increased number of BR cycles was associated with borderline increased SPM risk.  \nThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.  \n© 2026 The Author(s). Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.  \nCancer. 2026;e70327.  \n[https://doi.org/10.1002/cncr.70327](https://doi.org/10.1002/cncr.70327)  \nwi[leyonlinelibrary.com/journal/cncr](leyonlinelibrary.com/journal/cncr)  \n1 of 10  \nThese findings require prospective validation and studies examining risk-adapted abbreviation of chemotherapy.  \nKEYWORDS  \nbendamustine, counseling, delivery of health care, lymphoma, neoplasm, non-Hodgkin, Ontario, rituximab  \nINTRODUCTION  \nIndolent B-cell non-Hodgkin lymphomas (iBC","cbCairb4HemlmoIy","https://ap.wps.com/l/cbCairb4HemlmoIy","pdf",531495,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction\n## Overview of iBCL and frontline BR therapy\n## Evidence on SPM risk and inconsistencies\n## Risk-mitigation strategies","[{\"question\":\"What therapy and patient population were studied?\",\"answer\":\"The study evaluated frontline bendamustine-rituximab (BR) in adults (≥18 years) with untreated indolent B-cell non-Hodgkin lymphoma treated between 2013 and 2022, compared with a historical cohort treated with cyclophosphamide-based regimens between 2006 and 2012.\"},{\"question\":\"How was secondary primary malignancy (SPM) incidence measured?\",\"answer\":\"Five-year SPM incidence was analyzed using cumulative incidence function with competing-risk models, and a landmark analysis was performed at 6 months after the index date.\"},{\"question\":\"Did BR increase SPM risk compared with the older cyclophosphamide-based regimens?\",\"answer\":\"The 5-year cumulative incidence of SPM was higher for BR versus the historical regimens in univariate comparisons, but multivariable analysis showed no significant difference in SPM risk.\"},{\"question\":\"What was the effect of developing SPM on survival?\",\"answer\":\"Development of SPM shortened survival, with a hazard ratio reported as HR 3.67 (95% CI, 3.15–4.29, p \\u003c .001).\"}]","Secondary primary malignancies in indolent non-Hodgkin lymphoma patients receiving frontline bendamustine-rituximab | PDF",1790125323,25,[151,155,159,163],{"page_no":8,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c05d85490e218cef8852572fe61915dc.webp",983,1291,{"page_no":14,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/482b8a759dcde1ffcb5a7bf863e65d11.webp",982,1290,{"page_no":81,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5cfe7cd132bbd0dd737b0b00a7759a05.webp",981,1289,{"page_no":19,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b723d43150ece20e85f0fd7d052a21d3.webp",980,1287]